A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This project is a key clinical research project approved by the Clinical Research Center of
the First Affiliated Hospital of Xi 'an Jiaotong University.Tyrosine kinase inhibitors (TKI)
combined with chemotherapy and subsequent allogeneic hematopoietic stem cell transplantation
(allo-HSCT) are routinely used in patients with philadelpha-positive lymphoblastic leukemia
(Ph+ALL). However, TKI maintenance therapy post-HSCT remains controversial. In this study,
Ph+ALL patients are enrolled and given dasatinib combined with chemotherapy followed by
allo-HSCT. Then patients in the group A continuing to use dasatinib for 1 year is compared
with those in the group B receiving dasatinib for 6 months after HSCT. The measurable
residual disease (MRD), complete remission (CR), overall survival (OS), disease free survival
(DFS), non-relapse mortality (NRM) and the incidence of graft versus host disease (GVHD) will
be observed to determine the optimal duration of TKI maintenance therapy post-HSCT.
Phase:
N/A
Details
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University